Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 2017, according to a new report from U.S. Democratic Representative Katie Porter, a consumer bankruptcy law professor running for re-election in California.
Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
Non-small cell lung cancer (NSCLC) was a hot topic at the recent European Society for Medical Oncology (ESMO) Congress, where several researchers presented landmark findings, many of which are considered to be firsts. Such results portend advances that could significantly improve survival for patients with this common form of cancer.
Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said.
Amgen announced Tuesday morning that its initial Phase III data of its oral drug Lumakras (sotorasib) met its primary endpoint of progression-free survival in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
A small study of Amgen Inc.’s Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna.
One of the tenets of “personalized medicine” is that medications will be tailored to individuals based on their personalized genetics. Last year, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of them, were supported with genomic data.